EUVIMEDEUVIMED entdecken
Crossref

Letermovir as secondary prophylaxis of cytomegalovirus infection after allogeneic hematopoietic cell transplantation: A single center experience

Nihar Desai, Ivan Pasic iD, Arjun D Law iD, Wilson Lam, Armin Gerbitz, Auro Viswabandya, Dennis D Kim iD, Rajat Kumar iD, Jonas Mattsson, Igor Novitzky-Basso, Fotios V Michelis iD

European Journal of Haematology · 2024

DOI: 10.1111/ejh.14258 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Haematology, 2024. Verfasst von Nihar Desai und 10 weiteren Autor:innen. Beteiligte Einrichtung: Hans Messner Allogeneic Blood and Marrow Transplant Program, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, C…. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Cytomegalovirus Infections, Antiviral Agents, Quinazolines. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 32 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Letermovir, a novel anti‐cytomegalovirus (CMV) agent acts by inhibiting the viral terminase complex and is approved for primary prophylaxis in CMV seropositive patients post allogeneic hematopoietic cell transplantation (HCT). The favorable efficacy and safety profile make it an attractive option for use as secondary prophylaxis in patients at high‐risk for CMV reactivation. In this study, we report the efficacy and safety of letermovir secondary prophylaxis after at least one treated episode of CMV reactivation in a cohort of 39 high‐risk patients. Thirty two (82%) patients received anti‐thymocyte globulin (ATG), 27 (69%) received a combination of ATG and post‐transplant cyclophosphamide for graft‐versus‐host disease (GVHD) prophylaxis. Twenty one patients (54%) received CMV seronegative grafts. In addition, 18 (46%) patients had HLA mismatched unrelated or haploidentical donors while 18 (46%) had active GVHD requiring immunosuppression at the time of commencing secondary prophylaxis. Letermovir was initiated at a median of 47 days (range, 41–56) after HCT and was administered for a median duration of 77 days (range, 46–90). A single breakthrough CMV reactivation was noted in this high‐risk cohort. Four additional episodes of CMV reactivation occurred at a median of 28 days (range, 23–59 days) after discontinuation of secondary prophylaxis. The drug was well tolerated and 77% of the cohort completed the planned duration of secondary prophylaxis. None of the patients discontinued treatment due to treatment‐related adverse effects. In conclusion, letermovir is effective and well tolerated and may be considered for secondary prophylaxis in patients at high risk for CMV reactivation. Prospective studies are required to validate these findings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematopoietic Stem Cell TransplantationCytomegalovirus InfectionsAntiviral AgentsQuinazolinesTransplantation, HomologousAcetatesCytomegalovirusGraft vs Host DiseaseHumansMiddle AgedMaleFemaleAdultAgedVirus ActivationTreatment OutcomeSecondary PreventionYoung Adult

Stichwörter der Autor:innen

allogeneic hematopoietic cell transplantationcytomegalovirusletermovirsecondary prophylaxis

Substanzen

letermovirAntiviral AgentsQuinazolinesAcetates

Autor:innen und Institutionen

  • Hans Messner Allogeneic Blood and Marrow Transplant Program, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Canada.
  • Department of Medicine, University of Toronto, Toronto, Canada.

ORCID-Profile: Ivan Pasic, Arjun D Law, Dennis D Kim, Rajat Kumar, Fotios V Michelis

Zitieren

APA

Desai, N., Pasic, I., Law, A. D., Lam, W., Gerbitz, A., Viswabandya, A., Kim, D. D., Kumar, R., Mattsson, J., Novitzky-Basso, I., & Michelis, F. V. (2024). Letermovir as secondary prophylaxis of cytomegalovirus infection after allogeneic hematopoietic cell transplantation: A single center experience. European Journal of Haematology. https://doi.org/10.1111/ejh.14258

Vancouver

Desai N, Pasic I, Law AD, Lam W, Gerbitz A, Viswabandya A, et al. Letermovir as secondary prophylaxis of cytomegalovirus infection after allogeneic hematopoietic cell transplantation: A single center experience. European Journal of Haematology. 2024. doi:10.1111/ejh.14258

BibTeX
@article{Desai2024,
  author = {Desai, Nihar and Pasic, Ivan and Law, Arjun D and Lam, Wilson and Gerbitz, Armin and Viswabandya, Auro and Kim, Dennis D and Kumar, Rajat and Mattsson, Jonas and Novitzky-Basso, Igor and Michelis, Fotios V},
  title = {Letermovir as secondary prophylaxis of cytomegalovirus infection after allogeneic hematopoietic cell transplantation: A single center experience},
  journal = {European Journal of Haematology},
  year = {2024},
  doi = {10.1111/ejh.14258}
}
Kostenlos starten →